[New perspectives in cardiovascular risk reduction: focus on HDL].
Cardiovascular diseases represent the leading cause of morbidity and mortality worldwide, mostly contributing to hospitalizations and health care costs. Dyslipidemias represent one of the major cardiovascular risk factor and its management, throughout life-style modifications and pharmacological interventions, has shown to reduce cardiac events. The risk of adverse cardiovascular events is related not only to elevated LDL blood levels, but also to decreased HDL concentrations, that exhibit protective effects in the development of atherosclerotic process. Aim of this review is to summarize current evidences about defensing effects of such lipoproteins and to show the most recent pharmacological strategies to reduce cardiovascular risk through the increase of their circulating levels.
Department of Advanced Biomedical Sciences, Federico II University; Via Pansini 5, I-80131 Naples, Italy.
Stefania
S
Paolillo
Giuseppe Luca
GL
Della Ratta
Alice
A
Vitagliano
Annapaola
A
Cirillo
Elisabetta
E
Lardino
Tiziana
T
Formisano
Irma
I
Fabiani
Angela Maria
AM
Pellegrino
Pietro
P
Riello
Pasquale Perrone
PP
Filardi
D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D014943:Global Health; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008019:Life Style; D008075:Lipoproteins, HDL / Q000097:blood*; D009017:Morbidity / Q000639:trends; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends
D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL